SynthesisClinical reviews in allergy & immunology2013
Cutting-edge issues in coronary disease and the primary antiphospholipid syndrome.
Synthesis in Clinical reviews in allergy & immunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Acute myocardial infarction and antiphospholipid syndrome: an updated systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2025Review
- Antiphospholipid antibodies and atherosclerotic vascular disease: recent advances.Rheumatology international · 2025Review
- Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations.Rheumatology (Oxford, England) · 2024Review
- Review
- Anti-phospholipid syndrome and COVID-19 thrombosis: connecting the dots.Rheumatology advances in practice · 2021Review
- Cardiac Manifestations of Antiphospholipid Syndrome With Focus on Its Primary Form.Frontiers in immunology · 2019Review
- Article
- The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus.European journal of rheumatology · 2016Review
- Atherosclerotic vascular disease in the autoimmune rheumatologic patient.Current atherosclerosis reports · 2015Review
- Autoimmunity in 2013.Clinical reviews in allergy & immunology · 2014Review
- Unique topics and issues in rheumatology and clinical immunology.Clinical reviews in allergy & immunology · 2014Article
- The autoimmune side of heart and lung diseases.Clinical reviews in allergy & immunology · 2013Review
- Coronary heart disease in young adults.Current atherosclerosis reports · 2012Review
- Accelerated atherosclerosis in patients with SLE--mechanisms and management.Nature reviews. Rheumatology · 2012Review
- Seizures in primary antiphospholipid syndrome: the relevance of smoking to stroke.Clinical & developmental immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is the most frequent cause of venous and arterial thrombotic events in young patients. The brain arterial tree is primarily affected, but coronary ischemic manifestations are also relatively frequent. Coronary involvement was suggested to be closely related to the accelerated atherosclerosis linked to the underlying disease in APS associated to systemic autoimmune diseases, in particular, systemic lupus erythematosus. However, arterial ischemic events can occur in primary APS--with no other systemic disorders--even in the absence of traditional cardiovascular risk factors and overt atherosclerosis. From a biological point of view, this finding speaks in favor for a pro-coagulant activity of anti-phospholipid antibodies rather than for their role in atherosclerotic plaque formation. On the other hand, the clinical challenge is to avoid the risk to misdiagnose young patients with potentially life-threatening symptoms, such as myocardial infarction (MI). In fact, the occurrence of nonspecific symptoms related to coronary ischemic events is frequently misdiagnosed because of its rarity in young patients. This issue is well illuminated by two cases of MI in young patients reported in the manuscript together with a systematic review of the associations and implications of coronary ischemic events in APS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.